Double-targeting CDCA8 and E2F1 inhibits the growth and migration of malignant glioma

• Published in: Cell death & disease Vol. 12; no. 2; p. 146
• Main Authors: Wang, Xiaoxiong, Wang, Heping, Xu, Jiajun, Hou, Xu, Zhan, Haoqiang, Zhen, Yunbo
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01-02-2021; Springer Nature B.V; Nature Publishing Group
• Subjects: 13/51; 631/67; 692/699/67; Antibodies; Apoptosis; Biochemistry; Biomedical and Life Sciences; Brain cancer; Brain tumors; Cell adhesion & migration; Cell Biology; Cell Culture; Cell cycle; Cell division; Cell migration; Cell proliferation; Cell survival; DNA microarrays; Glioma; Glioma cells; Immunology; Life Sciences; Malignancy; Medical prognosis; Prognosis
• ISSN: 2041-4889; 2041-4889
• DOI: 10.1038/s41419-021-03405-4

High-grade glioma is the most common and aggressive primary brain tumor in adults with poor therapeutic efficiency and survival prognosis. Cell division cycle associated 8 (CDCA8) has been well known as a cell cycle regulator and tumor promotor in various malignant tumors. However, its biological role in glioma still remains unclear. Our results showed that high level of CDCA8 was significantly correlated with advanced WHO grade and poor overall survival and disease-free survival prognosis. In vitro and in vivo investigations demonstrated that CDCA8 promoted the glioma malignancy by promoting cell proliferation, cell migration, and inhibiting cell apoptosis. Moreover, we found its synergetic biological protein—E2F1 by the gene microarray chip. In this study, we revealed that CDCA8 synergized with E2F1 facilitated the proliferation and migration of glioma. In conclusion, our study provides a novel promising therapeutic targets and prognostic biomarkers for malignant glioma treatment.